InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.500 0.25 (33.33%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$240 Appendix 4C - quarterly 7 Apr 2009 9:15AM $0.270 $0.500 risen by 85.19%
$240 Raises additional capital via institutional placement 7 Apr 2009 9:14AM $0.270 $0.500 risen by 85.19%
$240 Trading Halt 3 Apr 2009 10:14AM $0.300 $0.500 risen by 66.67%
$240 Completes patient testing in retention of activity study 19 Mar 2009 12:24PM $0.190 $0.500 risen by 163.16%
$240 Half Yearly Report and Accounts 19 Feb 2009 4:55PM $0.170 $0.500 risen by 194.12%
$240 Topical Microbicide Field Boost With Efficacy Result 10 Feb 2009 1:10PM $0.200 $0.500 risen by 150%
$240 Appendix 4C - quarterly 30 Jan 2009 12:03PM $0.180 $0.500 risen by 177.78%
$240 Starpharma Dendrimer Reduces Toxicity of Cancer Drug 17 Dec 2008 1:11PM $0.230 $0.500 risen by 117.39%
$240 SPL7013 activity against all major HPV strains 4 Dec 2008 12:54PM n/a $0.500 n/a
$240 Appendix 4C - quarterly 31 Oct 2008 1:24PM $0.290 $0.500 risen by 72.41%
$240 Key VivaGel Patent Approved in Japan 30 Oct 2008 9:22AM $0.270 $0.500 risen by 85.19%
$240 VivaGel Condom Full Licence Agreement with Durex 9 Sep 2008 10:14AM $0.320 $0.500 risen by 56.25%
$240 Preliminary Final Report 27 Aug 2008 12:13PM $0.240 $0.500 risen by 108.33%
$240 VivaGel - New Clinical Trial Commences 13 Aug 2008 9:28AM $0.250 $0.500 risen by 100%
$240 Appendix 4C - quarterly 30 Jul 2008 1:00PM $0.265 $0.500 risen by 88.68%
$240 New Indication for VivaGel - Bacterial Vaginosis Treatment 9 Jul 2008 11:12AM $0.325 $0.500 risen by 53.85%
$240 Starpharma reports positive VivaGel clinical study results 12 May 2008 10:28AM $0.355 $0.500 risen by 40.85%
$240 Appendix 4C - quarterly 28 Apr 2008 1:38PM $0.345 $0.500 risen by 44.93%
$240 SPL7013 inhibits clinically relevant strains of HPV 21 Apr 2008 10:07AM $0.300 $0.500 risen by 66.67%
$240 Dendrimer SPL7013 potential application for arthritis 14 Apr 2008 10:57AM $0.330 $0.500 risen by 51.52%
$240 Shareholdings subject to security lending arrangement 7 Apr 2008 7:07PM $0.280 $0.500 risen by 78.57%
$240 Starpharma signs agreement with Unilever 7 Apr 2008 9:25AM $0.270 $0.500 risen by 85.19%
$240 Half Yearly Report and Accounts 21 Feb 2008 11:06AM $0.300 $0.500 risen by 66.67%
$240 Appendix 4C - quarterly 31 Jan 2008 10:12AM $0.350 $0.500 risen by 42.86%
$240 Expansion of VivaGel US trial and enrollment completion 8 Jan 2008 11:32AM $0.380 $0.500 risen by 31.58%

801 - 825 of 897 results

Page 33 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.